What is dyslipidemia?

    Last Updated: October 25, 2023

    Dyslipidemia is a condition where a person exhibits altered blood lipid metabolism. This shows up on bloodwork as abnormal levels of various cholesterols and/or fats, such as high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides.[1] Non-HDL cholesterol (Non-HDL-C), apolipoprotein B, and the ratio of total cholesterol to HDL-C may also be important metrics to examine in dyslipidemia.[2][3] Abnormalities in these markers and/or ratios are associated with increased risk of cardiovascular disease.[4] Changing certain markers may result in stronger clinical outcomes (non-HDL-C) than others (HDL-C).[5]

    References

    1. ^Mohr AE, Hatem C, Sikand G, Rozga M, Moloney L, Sullivan J, De Waal D, Handu DEffectiveness of medical nutrition therapy in the management of adult dyslipidemia: A systematic review and meta-analysis.J Clin Lipidol.(2022)
    2. ^Benoit J Arsenault, Jamal S Rana, Erik S G Stroes, Jean-Pierre Després, Prediman K Shah, John J P Kastelein, Nicholas J Wareham, S Matthijs Boekholdt, Kay-Tee KhawBeyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and womenJ Am Coll Cardiol.(2009 Dec 29)
    3. ^Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, Li D, Sievenpiper J, Duvnjak L, Vuksan VEffect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials.Am J Clin Nutr.(2018-Nov-01)
    4. ^Hsu HY, Lin CJ, Lee YS, Wu TH, Chien KLEfficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.BMC Cardiovasc Disord.(2020 Jul 13)
    5. ^Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA,National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.J Clin Lipidol.(2015)